Medication info

Ilyang Dapagliflozin Sustained-release Tablet 10/500 mg

Prescription medicationTabletOralApproval withdrawn
Ingredient · strength
Dapagliflozin citric acid›14.7mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Ilyang Pharmaceutical Co., Ltd.
Appearance
Pink, double convex, egg-shaped film-coated tablet
Packaging
30 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 202204068 · Approved 2022.11.10

This product's status changed to Approval withdrawn on 2023.10.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients who have not previously received pharmacologic treatment for diabetes and for whom adequate glycemic control cannot be achieved with monotherapy: When used as initial therapy in patients who have not previously received pharmacologic treatment for diabetes, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other glucose-lowering agents. Because changes may affect glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m2. In patients who tolerate this medicine well and have an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73m2 or higher and below 60 mL/min/1.73m2, with no other symptoms that may increase the risk of lactic acidosis, the metformin hydrochloride component of this medicine should be administered at a maximum dose of 1000 mg per day. If the eGFR falls below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases. The risk of volume depletion with dapagliflozin should be considered.

Ingredients

Manufacturer
Ilyang Pharmaceutical Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood glucose control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used to effectively improve blood glucose control in adult patients with type 2 diabetes in conjunction with dietary and exercise regimens through the co-administration of dapagliflozin and metformin. It should be used with caution in patients at risk of cardiovascular events, particularly in those whose blood glucose is not adequately controlled.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients who have not previously received pharmacologic treatment for diabetes and for whom adequate glycemic control cannot be achieved with monotherapy: When used as initial therapy in patients who have not previously received pharmacologic treatment for diabetes, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the doses of dapagliflozin and metformin previously being taken. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other glucose-lowering agents. Because changes may affect glycemic control, any change in the treatment of patients with type 2 diabetes should be made with careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m2. In patients who tolerate this medicine well and have an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73m2 or higher and below 60 mL/min/1.73m2, with no other symptoms that may increase the risk of lactic acidosis, the metformin hydrochloride component of this medicine should be administered at a maximum dose of 1000 mg per day. If the eGFR falls below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases. The risk of volume depletion with dapagliflozin should be considered.

Precautions

This medication is used to treat diabetes and helps control blood glucose levels. Caution is advised as it may pose risks for patients with decreased kidney function or acute kidney injury. This medication should not be administered to patients with severe infections, dehydration, cardiovascular issues, or liver dysfunction. Pregnant or breastfeeding women should also avoid using this medication. When used with other diabetes treatments, the risk of hypoglycemia may increase, hence dose adjustments may be required when combined with insulin or sulfonylureas. Rare side effects such as lactic acidosis can occur during use, so if symptoms such as fatigue, muscle pain, difficulty breathing, or abdominal discomfort appear, immediate medical attention should be sought. This medication may increase the risk of genital and urinary infections, so prompt treatment is necessary if infection symptoms develop. During the course of this medication, there may be a risk of decreased fluid volume or hypotension, so it is important to regularly monitor for dehydration symptoms or changes in blood pressure. Elderly patients or those with renal impairment should have adjusted dosages and regular kidney function tests are necessary. Before undergoing surgery or radiologic examinations with contrast media, this medication should be temporarily discontinued, and use should resume only after kidney function is confirmed to be normal post-examination. In the case of overdose, appropriate symptomatic treatment is necessary, and for the metformin component, dialysis may be helpful. This medication does not significantly affect the ability to drive or operate machinery; however, caution is necessary as dizziness may occur. Lastly, this medication should be stored out of the reach of children and must be kept in its original container to prevent degradation of quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvitis
  • balanitis
  • related genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated serum urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal impairment
  • rash
  • diarrhea
  • nausea
  • vomiting
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burns
  • wrist fractures
  • gastrointestinal stromal tumors
  • malignant neoplasms of the lung
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory abnormalities
  • drowsiness
  • tremors
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondritis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasions
  • itching
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. The storage temperature should be maintained between 1 degree and 30 degrees Celsius to ensure its effectiveness for a long period of time.

Appearance and packaging

Appearance

Pink, double convex, egg-shaped film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.